Curriculum Vitae
Jeffrey Statland, MD
Work Address:
Jeffrey Statland, MD
University of Kansas Medical Center
Assistant Professor, Department of Neurology
3901 Rainbow Boulevard
Kansas City, KS 66160
JStatland@KUMC.edu
Tel: 913-588-6970
FAX: 913-588-6965
Home Address:
7346 Roe Circle
Prairie Village, KS 66208
Tel 585-415-5123
Education
Department of Neurology, University of Rochester Medical Center, Rochester, NY
Fellowship in Experimental Therapeutics
2010-2012
Department of Neurology, Kansas University Medical Center, Kansas City, KS
Resident
2006-2010
University of Kansas School of Medicine, Kansas City, KS
M.D.
2000-2005
12/05
Emerson College, Boston, MA
M.F.A., Writing Literature, & Publishing
1992-1995
5/95
Sarah Lawrence College, Bronxville, NY
B.A.
1989-1991
5/91
Licensure
Kansas State medical license No. 04-37076
New York State medical license No. 259461
American Board of Psychiatry and Neurology license No.57229
04/2014-present
11/2010-09-2014
9/2011-present
Research
Fellow in Experimental Therapeutics / MDA Clinical Research Training Grant
Dr. Rabi Tawil, Professor of Neurology, Director, Fields Center for FSHD and
Neuromuscular Research
8/10-08/2014
Clinical Trial Preparedness in Facioscapulohumeral Muscular Dystrophy (FSHD). A
unifying genetic model for the mechanism of FSHD was recently discovered which raises
the hope for disease-directed therapies. However there is a need for sensitive and
specific outcome measures for FSHD to use in clinical trials. We plan to take a multitiered approach to develop reliable, patient relevant outcome measures for use in FSHD
clinical trials, biomarkers for use in early phase trials, and surrogate measures of
strength. Projects include 1) Molecular and imaging biomarkers for use in FSHD clinical
trials (MDA Research Grant, Tawil – PI) 2) electrical impedance myography as a noninvasive measure of muscle structure in FSHD (FSH Society Research Grant, Statland –
PI) and 3) a prospective study to evaluate a disease-specific PRO and functional grading
scale for FSHD (FSH-Society Research Grant, Statland – PI; and NIH Research Grant,
Heatwole – PI). In addition to our prospective studies we have performed a systematic
meta-analysis of measures of strength in FSHD (Neuromuscular Disorders 2013), and
surveyed a large national registry to better characterize the natural history of FSHD
(Muscle and Nerve 2013).
Consortium for Clinical Investigation in Neurological Channelopathies. I have
helped designed two projects for an upcoming NIH submission for a Rare Disease Clinical
Research Network: 1) a dose ranging and pharmacodynamics study of Bumetanide for
patients with genetically confirmed periodic paralysis; and 2) use of an interactive
telephone based electronic patient diary in patients with Myotonic Dystrophy. Building
on the collaborations and international infrastructure we created for our first CINCH
initiative we have designed new projects to realize the goal of academic translational
research – creating a pipeline for new therapeutics for these rare channelopathies.
Research Assistant/Resident
1/06-08/10
Dr. Richard Barohn, Chairman, Department of Neurology, Kansas University Medical
Center, Kansas City, KS
Nondystrophic Myotonias: genotype-phenotype correlation and longitudinal study.
This is a study sponsored by the National Institutes of Health/Office of Rare Diseases
looking at muscle membrane ion channel mutations and a variety of clinical and
electrophysiological measures of myotonia in subjects with Nondystrophic Myotonia. I
was responsible for editing the protocol, updating consent forms, recruiting and
examining patients. This work resulted in 2 manuscripts summarizing study data for an
Interactive Voice Response Diary and for a Quantitative Measure of Handgrip Myotonia
as potential outcome measures in therapeutic trials. I helped design and write the
protocol for an FDA orphan drug grant supported phase II cross over trial examining
mexiletine in Nondystrophic Myotonia. I was first author on this trial published in the
Journal of the American Medical Association. And I also helped write an NIH supported
grant, helped plan, and presented at an International Conference for the Nondystrophic
Myotonias.
Neuroimaging in Amyotrophic Lateral Sclerosis. I helped write the protocol, recruit
subjects, and examine initial data in a study comparing quality of life, measures of
spasticity and MRI volumetric analysis and DTI evaluation of the corticospinal tract in
subjects with amyotrophic lateral sclerosis.
Arimoclomol in sporadic Inclusion Body Myositis. I helped write the protocol for an
investigational study looking at the safety of arimoclomol, an upregulator of heat shock
2
proteins in subjects with sporadic Inclusion Body Myositis. The work from this study is
currently in manuscript.
Howard Hughes Medical Institute Research Scholar
8/02-6/03
Chris McBain, PhD, Chief, Laboratory of Cellular and Synaptic Neurophysiology, National
Institute of Child Health and Human Development, Bethesda, MD
Cholinergic stimulation from the septum induces theta oscillations in the
hippocampus which are necessary for memory formation. In this study, we used patch
clamp recording from acute mouse slices to investigate muscarine-induced changes in
intrinsic membrane conductances in hippocampal CA1 oriens/alveus (OA) interneurons.
And we propose alterations in these intrinsic conductances prime the local inhibitory
circuit to function in a theta-permissive state. Work from this period resulted in three
peer-reviewed publications.
National Institutes of Health Summer Research Internship
6/01-8/01
Mary Kay Floeter, M.D., PhD, section chief, EMG Section, National Institute of
Neurological Disorder and Stroke, Bethesda, MD
Primary Lateral Sclerosis (PLS) is a rare heterogenous disorder, characterized by
pure upper motor neuron degeneration and debilitating spasticity and dysarthria. We
examined patients with a previous diagnosis of PLS and grouped them according to
clinical course in the hopes of identifying a more homogenous subpopulation for future
study. We also examined changes in motor unit recruitment and investigated the
possibility of using vibration to correct the spasticity-related loss of coordination. Work
from this period resulted in two peer-reviewed publications.
Research Assistant
1/99-8/02
Edison Miyawaki, M.D., Department of Neurology, KUMC and Harvard University
We reviewed and wrote chapter entries on cerebral vasculature: arteries and
cerebral vasculature: veins for the Encyclopedia of the Neurological Sciences, and we
researched and wrote a review on the basal ganglia for a Harvard University student lab.
Work Experience
Assistant Professor
07/14-present
Department of Neurology, University of Kansas Medical Center, Kansas City, KS
Senior Instructor
08/12-06/14
Department of Neurology, University of Rochester Medical Center, Rochester, NY
Consultant
Cytokinetics – outcome measures for use in FSHD clinical trials
07/12-present
Fellowship in Experimental Therapeutics of neurological Disorders
08/10-08/12
Department of Neurology, University of Rochester Medical Center, Rochester, NY
Resident, Department of Neurology
7/07-6/10
3
Kansas University Medical Center, Kansas City, KS
Intern, Department of Medicine
Kansas University Medical Center, Kansas City, KS
7/06-7/07
Chemistry Tutor
Johnson County Community College, Overland Park, KS
5/99-7/00
Part-time Faculty in Expository Writing and U.S Multiculturalism
Emerson College, Boston, MA
9/93-5/94
Professional Memberships
American Academy of Neurology
2007-present
Honors/Scholarships/Grants
University of Kansas Medical Center KL2
2014-2016
FSH-Society Research Grant
2013-2014
MDA Clinical Research Training Fellowship
2012-2014
AAN platform presentation
2012
ANA 2011 Travel Fellowship
2011
Research Day Award, Department of Neurology
2008, 2010
Resident of the Year, Kansas University Medical Center
2008
Student Award Ambulatory Medicine Clerkship
2005
Student Award Neuropsychiatry Clerkship
2005
HHMI Continued Fellowship for Medical Education
2003-5
This competitive scholarship supplies $31,000/year for medical education and
living expenses
Alpha Omega Alpha
2004
Recognition of performance in Pharmacology
2003
Recognition of performance in Introduction to Clinical Medicine
2003
National Honors Pathology Society
2002
Deans List
MS1, MS2
Letter of Commendation, Anatomy
2001
Ad Hoc Reviewer / Scientific Advisory
Co-chair muscle disease session 2014 AAN National Meeting
Abstract reviewer for AAN National Meeting
Brain
New England Journal of Medicine
Neuromuscular Disorders
Muscle and Nerve
Annals of Neurology
Neuro NEXT protocol working group for lacosamide for NDM
4
2014
2013
2013-present
2012-present
2012-present
2011-present
2011-present
2011
Lectures
“FSHD: What we know, what we think we know, and what we have left to learn”, FSHD
Patient Day, Fields Center for FSHD Research, Rochester, NY, April, 2014.
“Facioscapulohumeral Muscular Dystrophy: recent advances and challenges for
therapeutic trials”, Grand Rounds, University of Rochester Medical Center, Feb,
2014.
“Muscle Channelopathies”, Neuromuscular Disease Conference, University of Rochester
Medical Center, Oct, 2013
“Bumetanide for Patients with Genetically Confirmed Hypokalemic Periodic Paralysis”,
Muscle Study Group, Oxford, UK, Sep 2013
“Natural History of FSHD: implications for clinical trials”, FSH Clinical Trials Working
Group, Netherlands, Apr 2013
“A Case of Sarcoid Myopathy”, Neuromuscular Disease Conference, University of
Rochester Medical Center, Oct, 2012
“Instrumented timed functional measures as possible outcome in FSHD”, Working Group
on Clinical Trials, University of Rochester Medical Center, March 2012
“Reevaluating Disease Progression in FSHD”, FSH Society International Workshop, Oct
2011
“Muscle Channelopathies”, Neuromuscular Disease Conference, University of Rochester
Medical Center, Sep, 2011
“Myotonic Dystrophy: a novel RNA mediated disease process”, Grand Rounds, University
of Kansas Medical Center, May 2010
Peer-Reviewed Publications
1.
2.
3.
4.
5.
6.
7.
Statland J, Phillips L, Trivedi JR. Muscle Channelopathies. Neurol Clin.
2014;32(3):801-15. Epub 2014/07/20. doi: 10.1016/j.ncl.2014.04.002.
PubMed PMID: 25037091.
Statland J, Tawil R. Facioscapulohumeral Muscular Dystrophy. Neurol Clin.
2014;32(3):721-8. Epub 2014/07/20. doi: 10.1016/j.ncl.2014.04.003. PubMed
PMID: 25037087.
Scully MA, Eichinger KJ, Donlin-Smith CM, Tawil R, Statland JM. Restrictive Lung
Involvement in Facioscapulohumeral Muscular Dystrophy. Muscle Nerve. 2014.
Epub 2014/03/19. doi: 10.1002/mus.24218. PubMed PMID: 24639337
Statland JM, Barohn RJ. Muscle channelopathies: the nondystrophic myotonias
and periodic paralyses. Continuum (Minneap Minn). 2013;19(6 Muscle
Disease):1598-614.
Statland JM, Tawil R. Risk of functional impairment in Facioscapulohumeral
muscular dystrophy. Muscle Nerve. 2014;49(4):520-7. Epub 2013/07/23. doi:
10.1002/mus.23949. PubMed PMID: 23873337.
Trivedi JR, Bundy B, Statland J, Salajegheh M, Rayan DR, Venance SL, et al. Nondystrophic myotonia: prospective study of objective and patient reported
outcomes. Brain. 2013;136(Pt 7):2189-200.
Statland JM, Ciafaloni E. Myasthenia gravis: Five new things. Neurology: Clinical
Practice. 2013;3(2):126-33.
5
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
Heatwole CR, Statland JM, Logigian EL. The diagnosis and treatment of myotonic
disorders. Muscle Nerve. 2013;47(5):632-48.
Statland JM, Sacconi S, Farmakidis C, Donlin-Smith CM, Chung M, Tawil R. Coats
syndrome in facioscapulohumeral dystrophy type 1: Frequency and D4Z4
contraction size. Neurology. 2013. Epub 2013/03/01. doi:
10.1212/WNL.0b013e3182897116. PubMed PMID: 23446679.
Statland JM, McDermott MP, Heatwole C, Martens WB, Pandya S, van der Kooi
EL, et al. Reevaluating measures of disease progression in facioscapulohumeral
muscular dystrophy. Neuromuscul Disord. 2013. Epub 2013/02/15. doi:
10.1016/j.nmd.2013.01.008. PubMed PMID: 23406877.
Statland JM, Bundy BN, Wang Y, Rayan DR, Trivedi JR, Sansone VA, et al.
Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a
randomized controlled trial. JAMA. 2012;308(13):1357-65.
Statland JM, Griggs RC, Augustine EF. Emerging Subspecialties in Neurology:
Fellowship in experimental therapeutics of neurologic disease. Neurology.
2012;79(13):e106-8.
Statland JM, Bundy BN, Wang Y, Trivedi JR, Raja Rayan D, Herbelin L, et al. A
quantitative measure of handgrip myotonia in non-dystrophic myotonia. Muscle
Nerve. 2012;46(4):482-9.
Statland JM, Tawil R. Facioscapulohumeral muscular dystrophy: molecular
pathological advances and future directions. Curr Opin Neurol 2011.
Statland JM, Wang Y, Richesson R, Bundy B, Herbelin L, Gomes J, Trivedi J,
Venance S, Amato A, Hanna M, Griggs R, Barohn RJ. An interactive voice
response diary for patients with non-dystrophic myotonia. Muscle Nerve
2011;44(1):30-35.
Singer MA, Statland JM, Wolfe GI, Barohn RJ. Primary lateral sclerosis. Muscle
Nerve 2007;35(3):291-302.
Lawrence JJ, Saraga F, Churchill JF, Statland JM, Travis KE, Skinner FK, McBain
CJ. Somatodendritic Kv7/KCNQ/M channels control interspike interval in
hippocampal interneurons. J Neurosci 2006;26(47):12325-12338.
Lawrence JJ, Grinspan ZM, Statland JM, McBain CJ. Muscarinic receptor activation
tunes mouse stratum oriens interneurones to amplify spike reliability. J Physiol
2006;571(Pt 3):555-562.
Lawrence JJ, Statland JM, Grinspan ZM, McBain CJ. Cell type-specific dependence
of muscarinic signalling in mouse hippocampal stratum oriens interneurones. J
Physiol 2006;570(Pt 3):595-610.
Floeter MK, Zhai P, Saigal R, Kim Y, Statland J. Motor neuron firing dysfunction in
spastic patients with primary lateral sclerosis. J Neurophysiol 2005;94(2):919927.
Zhai P, Pagan F, Statland J, Butman JA, Floeter MK. Primary lateral sclerosis: A
heterogeneous disorder composed of different subtypes? Neurology
2003;60(8):1258-1265.
Other Publications / Abstracts / Posters
1.
Statland JM, Donlin-Smith, C, Tapscott, SJ, van der Maarel, S, and Tawil R.
Multi-Analyte Profile of Potential Serum Biomarkers in Facioscapulohumeral
6
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
Muscular Dystroph (poster). FSH Society International Workshop (2013). Boston,
MA
Eichinger, K, Heatwole, C, Donlin-Smith, C, Tawil, R, and Statland, JM. Clinically
Relevant Outcome Measures for Facioscapulohumeral Muscular Dystrophy:
preliminary results from baseline testing (poster). FSH Society International
Workshop (2013). Boston, MA
Statland JM, and Tawil R. Natural History of FSHD: implications for trial design.
(platform). International clinical Trial Readiness Workshop (2013). Leiden,
Netherlands.
Statland JM, Tawil R, Venance SL. Andersen-Tawil Syndrome. In: Pagon RA, Bird TD, Dolan
CR, Stephens K, Adam MP, editors. GeneReviews. Seattle (WA)1993 (update 2013 Jan 03).
Rabi Tawil, Jeffrey Statland. Recent advances in facioscapulohumeral muscular
dystrophy. American Association of Neuromuscular and Electrodiagnostic Medicine
podcast, Ted Burns moderator, 2013.
Statland, JM, Martens, B, Tawil, R. Coats Syndrome in Facioscapulohumeral
Dystrophy Type 1: Frequency and D4Z4 Contraction Size. American Neurological
Association 2012 Meeting, Boston, MA.
Puwanant A, Statland J, Dilek N, Moxley R, Thornton C. Video Hand Opening Time
(vHOT) in Myotonic Dystrophy Type 1 (DM1) (P05.188). Neurology.
2012;78(Meeting Abstracts 1):P05.188.
Statland J, Martens W, Tawil A. Patient-Reported Disease Burden and Progression
in Genetically Confirmed Participants in a National Facioscapulohumeral Muscular
Dystrophy Registry (P04.083). Neurology. 2012;78(Meeting Abstracts 1):P04.083.
Statland J, Salajegheh M, Bundy B, Wang Y, Raja Rayan D, Trivedi J, et al. Phase
II Therapeutic Trial of Mexiletine in Non-Dystrophic Myotonia: Secondary
Outcomes Show Improvement in Symptoms and Signs of Myotonia (S55.005).
Neurology. 2012;78(Meeting Abstracts 1):S55.005.
Trivedi J, Bundy B, Raja Rayan D, Salajegheh M, Statland J, Venance S, et al.
Clinical and Molecular Characterization of Non-Dystrophic Myotonia (P05.181).
Neurology. 2012;78(Meeting Abstracts 1):P05.181.
Wang Y, He J, McVey A, Pasnoor M, Gallagher P, Herbelin L, Statland J, et al.
Twelve-Month Change of IBMFRS in the Arimocolomol Inclusion Body Myositis Pilot
Study (P07.225). Neurology. 2012;78(Meeting Abstracts 1):P07.225.
Statland JM and Tawil R. Regional Muscular Dystrophies (Chapter). The
Encyclopedia of the Neurological Sciences, 2nd Edition. 2012.
Statland J, Martens W, Pandya S et al. Reevaluating Disease Progression in
Facioscapulohumeral Dystrophy (Platform). FSHD Society International Workshop,
October 2011.
Statland J, Martens W, Pandya S et al. Reevaluating Disease Progression in
Facioscapulohumeral Dystrophy (Poster). American Neurological Association
Meeting, September 2011.
Statland, J.M., Bundy, B.N, Wang, Y., et al. A quantitative measure of handgrip
myotonia in nondystrophic myotonia (Poster). ICNMD, Italy, 2010.
Statland J, J Lawrence, Z Grinspan, C McBain. Multiple Muscarine-Sensitive
Conductances Prime Hippocampal CA1 Oriens/Alveus Interneurons for Local Circuit
Oscillations (Poster). Society for Neurosciences Conference, New Orleans, LA
2003.
7
17.
18.
Statland J, J Lawrence, C McBain. A KCNQ2-Like Conductance in the Sustained
Outward Current of Hippocampal CA1 Oriens/Alveus Interneurons (Poster). Society
for Neurosciences Conference, New Orleans, LA 2003.
E. Miyawaki, J. Statland. Cerebral Blood Vessels: arteries and Cerebral Blood
Vessels: veins, chp.s in Encyclopedia of the Neurological Sciences, K. Graham, Ed.
Elsevier: New York, 2003. p.p. 584-594.
Research Support
KL2TR000119
Statland (PI)
The Relationship of Electrical Impedance Myography to Muscle Structure and Function in
Facioscapulohumeral Muscular Dystrophy (REM-FSH)
07/2014-present
FSH-Society Research Project Grant
Electrical Impedance Myography in FSHD
Statland (PI)
7/2013-12/2014
FSH-Society Research Project Grant
Clinical Trial Preparedness in FSHD
Statland (PI)
2/2013-8/2014
MDA Clinical Research Training Grant
07/2012-present
T32 NS07338-20
Griggs (PI)
Experimental Therapeutics in Neuromuscular Disorders
The goal of this project is to develop clinical and translational researchers in neurology
Role: Fellow
08/2010-07/2012
8